168 related articles for article (PubMed ID: 21399868)
1. p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
Yang SX; Steinberg SM; Nguyen D; Swain SM
Int J Oncol; 2011 May; 38(5):1445-52. PubMed ID: 21399868
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.
Yang SX; Steinberg SM; Nguyen D; Wu TD; Modrusan Z; Swain SM
Clin Cancer Res; 2008 Sep; 14(18):5893-9. PubMed ID: 18794102
[TBL] [Abstract][Full Text] [Related]
3. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
6. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
9. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
von Minckwitz G; Loibl S; Untch M; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Huober J; Solbach C; Jackisch C; Kunz G; Blohmer JU; Hauschild M; Fehm T; Nekljudova V; Gerber B; ; Gnauert K; Heinrich B; Prätz T; Groh U; Tanzer H; Villena C; Tulusan A; Liedtke B; Blohmer JU; Kittel K; Mau C; Potenberg J; Schilling J; Just M; Weiss E; Bückner U; Wolfgarten M; Lorenz R; Doering G; Feidicker S; Krabisch P; Deichert U; Augustin D; Kunz G; Kast K; von Minckwitz G; Nestle-Krämling C; Rezai M; Höß C; Terhaag J; Fasching P; Staib P; Aktas B; Kühn T; Khandan F; Möbus V; Solbach C; Tesch H; Stickeler E; Heinrich G; Wagner H; Abdallah A; Dewitz T; Emons G; Belau A; Rethwisch V; Lantzsch T; Thomssen C; Mattner U; Nugent A; Müller V; Noesselt T; Holms F; Müller T; Deuker JU; Schrader I; Strumberg D; Uleer C; Solomayer E; Runnebaum I; Link H; Tomé O; Ulmer HU; Conrad B; Feisel-Schwickardi G; Eidtmann H; Schumacher C; Steinmetz T; Bauerfeind I; Kremers S; Langanke D; Kullmer U; Ober A; Fischer D; Kohls A; Weikel W; Bischoff J; Freese K; Schmidt M; Wiest W; Sütterlin M; Dietrich M; Grießhammer M; Burgmann DM; Hanusch C; Rack B; Salat C; Sattler D; Tio J; von Abel E; Christensen B; Burkamp U; Köhne CH; Meinerz W; Graßhoff ST; Decker T; Overkamp F; Thalmann I; Sallmann A; Beck T; Reimer T; Bartzke G; Deryal M; Weigel M; Huober J; Weder P; Steffens CC; Lemster S; Stefek A; Ruhland F; Hofmann M; Schuster J; Simon W; Kronawitter U; Clemens M; Fehm T; Janni W; Latos K; Bauer W; Roßmann A; Bauer L; Lampe D; Heyl V; Hoffmann G; Lorenz-Salehi F; Hackmann J; Schlag R
Ann Oncol; 2014 Dec; 25(12):2363-2372. PubMed ID: 25223482
[TBL] [Abstract][Full Text] [Related]
10. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
[TBL] [Abstract][Full Text] [Related]
13. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
14. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
16. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Quintela-Fandino M; Holgado E; Manso L; Morales S; Bermejo B; Colomer R; Apala JV; Blanco R; Muñoz M; Caleiras E; Iranzo V; Martinez M; Dominguez O; Hornedo J; Gonzalez-Cortijo L; Cortes J; Gasol Cudos A; Malon D; Lopez-Alonso A; Moreno-Ortíz MC; Mouron S; Mañes S
Breast Cancer Res; 2020 Nov; 22(1):124. PubMed ID: 33176887
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
Wedam SB; Low JA; Yang SX; Chow CK; Choyke P; Danforth D; Hewitt SM; Berman A; Steinberg SM; Liewehr DJ; Plehn J; Doshi A; Thomasson D; McCarthy N; Koeppen H; Sherman M; Zujewski J; Camphausen K; Chen H; Swain SM
J Clin Oncol; 2006 Feb; 24(5):769-77. PubMed ID: 16391297
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
